retatrutide phase 2 trial obesity nejm 2023 Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) 2023年度回顧】 NEJM Notable Articles of

Sleep: the overlooked reset amplifier Poor sleep actively works against GLP-1 receptor sensitivity

Every time a provider prescribes a medication, there is a risk of adverse side effects for the patient, but those risks are often outweighed by the benefit of taking the medication

Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity

The long term lens We talk about GLP-1s in terms of the person taking them

Each has different pricing structures, medication options, and medical oversight levels

North America currently leads the global GLP-1 analogue market, driven by high obesity rates, strong reimbursement frameworks, and proactive healthcare systems